Manila Times Business
ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026
-Updateddata across two dose levels of 200 mW/cm and 400 mW/cmin LA-PDAC trialshow71% (5/7) patients resected following VTP with a consistent and well-tolerated safety profile- - Early clinical observations of Padeliporfin VTP in LA-PDAC support advancement of the program with potential for accelerated registrational pathway, strengthened by robust efficacy and durability data in LG-UTUC - -Complete response (CR) observed in 70% of evaluablepatientswith LG-UTUC who completed Primary Response Eva
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
1h ago
Ghana's 'anti-LGBTQ' law triggers both praise and outrage
2h ago
WHO chief visits epicentre of Ebola outbreak in DR Congo
2h ago
Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About
2h ago